An observational study in Cognitive Dysfunction, Cognitive Dysfunction, Cognitive Disorder and Parkinson's Disease (PD), sponsored by Yantai Yuhuangding Hospital. Enrolling by invitation at 2 sites in China. Open to participants aged 55 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Yantai Yuhuangding Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.
Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 64th largest by planned enrollment of the 119 observational ones that give a count, is one of 45 that started in 2026, is one of 119 observational ones, reaches primary completion later than 128 of the 155 other live ones, and was the 271st registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:
Central South University · Sites in China
Ages 18–35
Shanghai University of Sport · Sites in China
Ages 60–80
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Sites in China
Ages 35–80
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Shanghai University of Sport · Sites in China
Ages 65+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 55 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
310 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 17 · Phase 4 15
First in 2000; this study’s year is marked. 45 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 110 across the 191 interventional studies, 300 across the 119 observational. Of the 90 that completed or were terminated, 3 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 310 have an industry lead sponsor. The 10 most frequent:
Yantai Yuhuangding Hospital is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Yantai Yuhuangding Hospital has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
34 of the studies in Cognitive Dysfunction with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
| NCT06417086ZhanYJClinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers | 2026-11-30 |
| NCT07760415Xiangya Hospital of Central South UniversityEEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes | 2026-12-12 |
| NCT03810794Jian Pei,MDClinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease | 2026-12-30 |
Add all 34 to your calendar (.ics) → With an account.
Among the 310 studies in Cognitive Dysfunction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study aimed at understanding the cognitive, functional, and behavioral characteristics of Chinese patients with cognitive impairment, exploring the underlying mechanisms, and providing evidence for early diagnosis, treatment, and care of cognitive disorders including dementia.
Eligible participants will undergo a series of assessments and examinations, including cognitive and memory scale tests, routine blood tests, ApoE genetic testing, cerebrospinal fluid testing, brain MRI, functional MRI, and FDG-PET/AV45-PET scans when necessary. Additional samples such as saliva, nasal secretions, and stool may also be collected. Most evaluations are provided free of charge to support diagnosis and treatment guidance.
Participation is voluntary. All personal information and research data will be kept confidential. Potential benefits include access to expert clinical care and free cognitive assessments for disease evaluation. Possible inconveniences include time commitment and temporary discomfort during examinations; medical support will be provided if needed.
Participants were recruited from Yantai Yuhuangding Hospital, Yantai, Shandong Province, China.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Malignant tumors. Family history of genetic disorders.
Degree and Type of Cognitive Impairment Assessed by Neuropsychological Scales
Higher scores indicate better cognitive function; lower scores indicate more severe cognitive impairment.
Time frame: From enrollment to the end of treatment at 3 years
Plan to share: No — IPD will not be shared due to privacy regulations, ethical requirements, and limitations specified in the informed consent document.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 35 months is below that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yantai Yuhuangding Hospital